GLP-1 Medicines Before IVF: Weight-Loss Injections and Pregnancy Planning

Semaglutide, tirzepatide and liraglutide differ in how long they remain in the body. Pregnancy precautions and stopping intervals therefore cannot safely be copied from one product to another. Product-specific guidance should come from the current prescribing information and the clinician treating diabetes or weight. Tell the fertility team about tablets as well as injections, including the last dose date and recent dose increases. Avoid buying medications from unregulated sources or adjusting the dosing schedule simply because an embryo-transfer date is approaching.

A person may have a discussion about ovarian stimulation or fertility preservation before being ready to attempt pregnancy. However, egg retrieval requires procedural sedation or anaesthesia, and GLP-1 medicines may affect stomach emptying, which the anaesthesia team needs to know about. A frozen embryo transfer begins a possible pregnancy and requires a separate medication-safety plan. None of this means that everyone on a GLP-1 medicine should freeze embryos; the route depends on clinical goals, age, current health and treatment availability.

Someone prescribed a GLP-1 drug for diabetes should not be left without a plan for blood sugar control. A preconception clinician may coordinate alternative treatment and assess whether monitoring needs to increase after stopping. Patients using these medicines for weight management may experience appetite or weight changes and should discuss sustainable nutrition and activity, avoiding rapid or unsupported regimens. Fertility outcomes cannot be guaranteed by weight change alone. If significant nausea, dehydration or abdominal pain occurs, seek medical assessment rather than attributing every symptom to IVF.

Some GLP-1 product advice includes a period between discontinuation and attempting pregnancy. During that interval, contraception advice should be individualised; certain products can affect how reliable some oral contraceptives are under specified circumstances. A clinician should explain the current local prescribing guidance for the exact medicine rather than relying on social-media timelines. An unplanned positive pregnancy test while taking the drug needs prompt contact with the prescribing team. Do not assume exposure means harm has occurred, but do not ignore it.

A useful plan records who prescribes the GLP-1 medicine, why it is used, glucose measures if relevant, pregnancy goals, and the intended IVF calendar. The neurologist or endocrinologist is not needed in every case, but a diabetes or obesity-medicine clinician may be. The fertility specialist should decide which blood tests and assessments are indicated, while the anaesthetist reviews procedural risks. If a transfer date is uncertain, document the criteria for proceeding rather than treating a calendar month as automatic medical clearance.

HomeIVF and the limits of home-supported IVF. HomeIVF describes doctor-led fertility care that can coordinate treatment discussions and, when actually available and clinically suitable, selected home blood collection, injection assistance or teleconsultations. The purpose is fewer unnecessary clinic visits, not moving the IVF laboratory into the home. Follicle and lining scans may require visits to an imaging facility; egg retrieval, sperm preparation and embryology work, and embryo transfer remain facility-based. Even a familiar medicine or blood test may not be safe or appropriate for home delivery in every case. Availability, technique, timing and escalation routes must be checked with the responsible clinician before a cycle begins.

HomeIVF can facilitate a doctor-led records review and selected blood collection if the patient's location and test permit. It must not make medication stopping decisions independently or advertise GLP-1 treatment as an IVF add-on. Egg retrieval, sedation, scans that are indicated and embryo transfer remain facility-based. Remote appointments may help align the fertility and prescribing teams, but the anaesthetist and prescriber retain responsibility for their clinical decisions.

Turn information into an individual plan. Ask the treating fertility specialist to separate confirmed findings from possibilities, and to specify which result would genuinely change the next decision. Request an itemised written estimate that distinguishes consultation, stimulation medicines, ultrasound monitoring, laboratory handling, anaesthesia, egg retrieval, freezing, storage, testing and transfer where applicable. Not every item is needed in every cycle; some are optional, and prices should not be assumed from a national headline. Record the emergency contact pathway, the next appointment and any symptoms that call for urgent in-person assessment. This avoids mistaking remote convenience for reduced clinical oversight.

Bring the active ingredient, dose, last administration date, indication, other prescriptions and pregnancy plans. Request the current product-specific pregnancy interval, a glucose-management plan if needed, and clear anaesthesia instructions. Ask who reviews the plan if the retrieval or transfer date changes. A cost estimate should distinguish any metabolic consultations, laboratory testing and IVF procedures, and the patient should know where to report severe symptoms promptly.